Biotech | March 11, 2022
First-in-human trial in US for Gan & Lee type 2 diabetes drug
The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers
The primary objective of this Phase 1 study is to investigate the safety and tolerability of GZR18 in healthy volunteers
A total of 21 applicants have been approved for 49 products, with the potential to utilize an incentive amount of Rs. 2541 crore
The Mechanisms of Inherited Kidney Disorders (MIKADO) group at the University of Zurich (UZH) and Insilico Medicine will be working together to identify, rank, and annotate novel drug targets to identify potential therapeutics for cystinosis
Women's health is in fact a direct reflection of the nation's overall health
The breakthrough approval expands the existing indication of Jardiance to include adults with heart failure with preserved ejection fraction (HFpEF), an underserved patient population that previously had no approved therapies in Europe
Technology adoption helped the industry to sail through Covid-19 disruption as it understood the need to digitize, learn, and excel
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
The company, already scaling across Europe, plans to accelerate the deployment of its medication reconciliation platform in the United States
The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
N Yuvraj, Joint Secretary, Dept of Pharmaceuticals, Satish Reddy, Chairman, Dr Reddy’s Laboratories; Kiran Mazumdar Shaw, Executive Chairperson, Biocon Group; Sanjiv Navangul, MD & CEO, Bharat Serums and Vaccines and Shravil Patel, MD, Zydus Lifesciences discuss the way forward for the India pharma industry
Subscribe To Our Newsletter & Stay Updated
